Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Reduction in Costs, Blood Products, and Operating Time in Patients Undergoing Open Heart Surgery

Reduction in Costs, Blood Products, and Operating Time in Patients Undergoing Open Heart Surgery Abstract Objective: To test the hypothesis that use of aprotinin at half dose would be more cost-effective or as efficacious as full-dose aprotinin or no aprotinin during open heart surgery. Design: Cost-effective analysis, unmasked prospective comparison. Setting: Community hospital. Patients: One hundred thirty-three patients undergoing open heart surgery. Interventions: Patients in 3 consecutive groups undergoing open heart surgery were allocated to receive no aprotinin, full-dose aprotinin, or half-dose aprotinin. Main Outcome Measures: Total cost (in dollars) of blood products administered plus cost of aprotinin at various dosages, comparison of total blood products administered during hospitalization, and closure time required in the operating room. Results: Full-dose and half-dose aprotinin significantly (P<.05) reduced the total blood products administered during hospitalization and the operating room closure time. However, use of half-dose aprotinin resulted in a significant cost savings (P<.05) when compared with either the cost of blood products required in the nodose aprotinin group or the cost of blood products plus aprotinin in the full-dose aprotinin group. Conclusion: Use of aprotinin at half dose in a community hospital resulted in a significant reduction in costs, blood product use, and operating room closure time in patients undergoing open heart surgery.Arch Surg. 1997;132:858-861 References 1. Bidstrup BP, Royston DM, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol) . J Thorac Cardiovasc Surg . 1989;97:364-372. 2. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study . Ann Thorac Surg . 1992; 54:1031-1038.Crossref 3. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency . J Thorac Cardiovasc Surg . 1994;107:543-553. 4. Davis R, Whittington R. Aprotinin: a review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery . Drugs . 1995; 49:954-983.Crossref 5. Schönberger JPAM, Everts PAM, Ercan H, et al. Low-dose aprotinin in internal mammary artery bypass operations contributes to important blood saving . Ann Thorac Surg . 1992;54:1172-1176.Crossref 6. Liu B, Tengborn L, Larson G, et al. Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations . Ann Thorac Surg . 1995;59:1534-1540.Crossref 7. Levy JH, Pifarre R, Schaff HV, et al. A multicenter double-blind, placebocontrolled trial of aprotinin for reducing blood loss and the requirement for donorblood transfusion in patients undergoing repeat coronary artery bypass grafting . Circulation . 1995;92:2236-2244.Crossref 8. Lemmer JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens . Ann Thorac Surg . 1996;62:1659-1668.Crossref 9. Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CRH. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass . Ann Thorac Surg . 1991;51:936-941.Crossref 10. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorto-coronary bypass graft patency . J Thorac Cardiovasc Surg . 1993; 55:147-153. 11. Wendel HP, Heller W, Michel J, Mayer G, Ochsenfahrt C, Graeter U. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage . J Thorac Cardiovasc Surg . 1995;108:1164-1172.Crossref 12. Levy JH, Ramsay JG, Murkin J. Aprotinin reduces the incidence of strokes following cardiac surgery . Circulation . 1996;94( (suppl) ):l-535. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Surgery American Medical Association

Reduction in Costs, Blood Products, and Operating Time in Patients Undergoing Open Heart Surgery

Loading next page...
 
/lp/american-medical-association/reduction-in-costs-blood-products-and-operating-time-in-patients-uow1YK0ClI
Publisher
American Medical Association
Copyright
Copyright © 1997 American Medical Association. All Rights Reserved.
ISSN
0004-0010
eISSN
1538-3644
DOI
10.1001/archsurg.1997.01430320060009
Publisher site
See Article on Publisher Site

Abstract

Abstract Objective: To test the hypothesis that use of aprotinin at half dose would be more cost-effective or as efficacious as full-dose aprotinin or no aprotinin during open heart surgery. Design: Cost-effective analysis, unmasked prospective comparison. Setting: Community hospital. Patients: One hundred thirty-three patients undergoing open heart surgery. Interventions: Patients in 3 consecutive groups undergoing open heart surgery were allocated to receive no aprotinin, full-dose aprotinin, or half-dose aprotinin. Main Outcome Measures: Total cost (in dollars) of blood products administered plus cost of aprotinin at various dosages, comparison of total blood products administered during hospitalization, and closure time required in the operating room. Results: Full-dose and half-dose aprotinin significantly (P<.05) reduced the total blood products administered during hospitalization and the operating room closure time. However, use of half-dose aprotinin resulted in a significant cost savings (P<.05) when compared with either the cost of blood products required in the nodose aprotinin group or the cost of blood products plus aprotinin in the full-dose aprotinin group. Conclusion: Use of aprotinin at half dose in a community hospital resulted in a significant reduction in costs, blood product use, and operating room closure time in patients undergoing open heart surgery.Arch Surg. 1997;132:858-861 References 1. Bidstrup BP, Royston DM, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol) . J Thorac Cardiovasc Surg . 1989;97:364-372. 2. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study . Ann Thorac Surg . 1992; 54:1031-1038.Crossref 3. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency . J Thorac Cardiovasc Surg . 1994;107:543-553. 4. Davis R, Whittington R. Aprotinin: a review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery . Drugs . 1995; 49:954-983.Crossref 5. Schönberger JPAM, Everts PAM, Ercan H, et al. Low-dose aprotinin in internal mammary artery bypass operations contributes to important blood saving . Ann Thorac Surg . 1992;54:1172-1176.Crossref 6. Liu B, Tengborn L, Larson G, et al. Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations . Ann Thorac Surg . 1995;59:1534-1540.Crossref 7. Levy JH, Pifarre R, Schaff HV, et al. A multicenter double-blind, placebocontrolled trial of aprotinin for reducing blood loss and the requirement for donorblood transfusion in patients undergoing repeat coronary artery bypass grafting . Circulation . 1995;92:2236-2244.Crossref 8. Lemmer JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens . Ann Thorac Surg . 1996;62:1659-1668.Crossref 9. Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CRH. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass . Ann Thorac Surg . 1991;51:936-941.Crossref 10. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorto-coronary bypass graft patency . J Thorac Cardiovasc Surg . 1993; 55:147-153. 11. Wendel HP, Heller W, Michel J, Mayer G, Ochsenfahrt C, Graeter U. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage . J Thorac Cardiovasc Surg . 1995;108:1164-1172.Crossref 12. Levy JH, Ramsay JG, Murkin J. Aprotinin reduces the incidence of strokes following cardiac surgery . Circulation . 1996;94( (suppl) ):l-535.

Journal

Archives of SurgeryAmerican Medical Association

Published: Aug 1, 1997

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month